278 related articles for article (PubMed ID: 28082112)
1. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Rousselot P; Mollica L; Guilhot J; Guerci A; Nicolini FE; Etienne G; Legros L; Charbonnier A; Coiteux V; Dartigeas C; Escoffre-Barbe M; Roy L; Cony-Makhoul P; Dubruille V; Gardembas M; Huguet F; Réa D; Cayssials E; Guilhot F; Bergeron A; Molimard M; Mahon FX; Cayuela JM; Busque L; Bouchet S
Br J Haematol; 2021 Jul; 194(2):393-402. PubMed ID: 34195988
[TBL] [Abstract][Full Text] [Related]
3. Nodular histiocytic hyperplasia: Is this a cause of dasatinib-pleural effusion?
Hamada S; Hayashi E; Tsukino M
Arch Bronconeumol; 2017 Apr; 53(4):212-213. PubMed ID: 27825730
[No Abstract] [Full Text] [Related]
4. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
5. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
7. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
Kim D; Goh HG; Kim SH; Cho BS; Kim DW
Int J Hematol; 2011 Oct; 94(4):361-371. PubMed ID: 21901399
[TBL] [Abstract][Full Text] [Related]
8. A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion.
Alter A; Chaisson N; Mukherjee S; Gildea T
Chest; 2018 Feb; 153(2):e33-e36. PubMed ID: 29406237
[TBL] [Abstract][Full Text] [Related]
9. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Suh KJ; Lee JY; Shin DY; Koh Y; Bang SM; Yoon SS; Park S; Kim I; Lee JO
Int J Hematol; 2017 Aug; 106(2):229-239. PubMed ID: 28378056
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib-induced chylothorax: report of a case and review of the literature.
Chen B; Wu Z; Wang Q; Li W; Cheng D
Invest New Drugs; 2020 Oct; 38(5):1627-1632. PubMed ID: 32248338
[TBL] [Abstract][Full Text] [Related]
11. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
Krauth MT; Herndlhofer S; Schmook MT; Mitterbauer-Hohendanner G; Schlögl E; Valent P
Haematologica; 2011 Jan; 96(1):163-6. PubMed ID: 20934998
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.
McCafferty EH; Dhillon S; Deeks ED
Paediatr Drugs; 2018 Dec; 20(6):593-600. PubMed ID: 30465234
[TBL] [Abstract][Full Text] [Related]
13. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
14. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Maral S; Bakanay SM; Kucuksahin O; Dilek I
J Oncol Pharm Pract; 2020 Apr; 26(3):738-741. PubMed ID: 31359838
[TBL] [Abstract][Full Text] [Related]
15. An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
McBride A; Brokars J; Reddy SR; Chang E; Tarbox MH; LeBlanc TW
Acta Haematol; 2023; 146(4):259-266. PubMed ID: 37037194
[TBL] [Abstract][Full Text] [Related]
16. Is dasatinib-related pulmonary hypertension a clinical concern?
Szmit S
Future Oncol; 2015 Sep; 11(18):2491-4. PubMed ID: 26278893
[No Abstract] [Full Text] [Related]
17. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
Masiello D; Gorospe G; Yang AS
J Hematol Oncol; 2009 Nov; 2():46. PubMed ID: 19909541
[TBL] [Abstract][Full Text] [Related]
18. Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
Tsuchiya S; Takaku T; Watanabe N; Iriyama N; Kimura Y; Iwanaga E; Sugimoto KJ; Mitsumori T; Ishikawa M; Nakazato T; Fujita H; Sato E; Hatta Y; Asou N; Kizaki M; Tokuhira M; Ando M; Kawaguchi T
Intern Med; 2023 Nov; 62(22):3299-3303. PubMed ID: 37005261
[TBL] [Abstract][Full Text] [Related]
19. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib-induced Chylothorax in Chronic Myeloid Leukemia.
Alqattan Y; Ali S; Almohammad R; Kayali N; Alhuraiji A
Gulf J Oncolog; 2022 Sep; 1(40):74-77. PubMed ID: 36448074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
